cells required for the generation of suppressor B cells by LPS. Lipopolysaccharide (LPS), primarily recognized as an immune adjuvant, also induces immune suppression. Both immune enhancement and immune suppression may occur simultaneously and, depending on the experimental conditions, one or the other may predominate. We have demonstrated that LPS enhances the antigen-dependent production of antibody in vitro by causing macrophages to release a B-cell differentiation factor (BDF). BDF stimulates antibody formation in the absence of helper T cells and of macrophages. BDF also selectively induces the phenotypic differentiation of B cells (1) (2) (3) . LPSinduced immune suppression, by contrast, does not involve macrophages. We report here that LPS directly activates suppressor cells which carry the characteristic surface markers of B lymphocytes.
MATERIALS AND METHODS
Mice. Eight-to 12-week-old C57BL/6, (C57BL/6 X DBA/2)FI, and CeHeB/FeJ female mice were purchased from Jackson Laboratory. C57BL/6-H-2k, C57BL/6-Ly-B-2.1-StrB, and C57BL/6-Pc-l+ were obtained from our own breeding colony.
Antisera. A.TH anti-A.TL (anti-Iak), rabbit anti-MOPC 104 E (anti-IgM), rabbit anti-F(ab)2 fragment of MOPC 21 (antiIgG), and (A/Thy 1.1 X AKRH-2b)F, anti-ASL/1 (anti-Thy 1.2), raised as described (4) , were supplied by U. Hammerling (Sloan-Kettering Institute, New York). (C3H.I X C57BL/6)F1 anti-I.29 (anti-Ly-b-2.1) and (DBA/2 X C57BL/6)Fl anti-MOPC 70 A (anti-Pc-1) were prepared (5, 6) by F. W. Shen (Sloan-Kettering Institute, New York). The 19S fraction of rabbit anti-sheep erythrocytes (SRBC) was purchased from Cordis Laboratories (Miami, FL). Rabbit anti-concanavalin A was prepared as described (7) .
T-Cell Replacing Factor. Tumor necrosis serum (TNS) prepared in CD-1 mice was obtained from E. Carswell (Sloan-Kettering Institute, New York). T-cell replacing factors in this serum have been described (8) .
LPS. LPS prepared from Salmonella abortus-equi, its sodium and triethylamine salt forms, and lipid A triethylamine, were provided by Chris Galanos (Freiburg, Germany). LPS from Salmonella minnesota S445 was supplied by Markus Simon (Heidelberg, Germany).
Antigens. SRBC were obtained from the Colorado Serum Company (Denver, CO).
Cell Culture. Spleen cells were cultured according to the method of Mishell and Dutton (9) except for the addition of 50 ,uM 2-mercaptoethanol to the culture medium (10) . Two-phase cultures were set up as follows. One set of spleen cell cultures (recipient cultures) containing 0.6 or 0.7 ml of cells (107/ml) in complete medium (9) was set up in 35-mm dishes and immunized with SRBC. Another set of spleen cell cultures was initiated at the same time in the presence and absence of 10 ,ug of LPS. These cells were usually passed over Sephadex G-10 columns first to remove macrophages. After [20] [21] [22] [23] [24] hr, the cells were harvested by tituration and washed twice in medium. Treatment of cells with antiserum and complement was performed at this time. Graded numbers (as indicated) were transferred in 0.4-or 0.3-ml volumes to the recipient cultures. Control cultures, to which no cells were transferred, received an equal volume of medium. Assays for plaque-forming cells (PFC) were performed 3 days later.
Cell Preparations. Macrophages were removed from spleen cell suspensions by passing them through Sephadex G-10 columns as described by Ly and Mishell (11) . Cells bearing a receptor for the third component of complement (CR+ cells) were removed by passage over Sephadex G-10 columns coated with antigen-antibody-complement complexes (7) . Fractions of spleen cells rich in CR+ or CR-cells were prepared by rosetting CR+ lymphocytes with antibody and complementcoated erythrocytes and separating them from nonrosetted lymphocytes on a 1 X g velocity sedimentation gradient (12) .
Cytotoxicity Test. A two-step test was performed by incubating cells (1-5 X 107 cells) with antiserum on ice for 30 min, pelleting the cells, and then resuspending them in 1:10 dilution of rabbit serum (complement) followed by incubation at 370C for 35 min. The cells were then washed twice and resuspended in complete medium. Aliquots of cells treated with antiserum (and complement) were resuspended before use to the volume of the control cells which were treated with complement alone.
Assay for PFC. Cells producing antibody to SRBC were enumerated by the Jerne-Nordin hemolytic plaque assay (13) as modified by Mishell and Dutton (9 The time of LPS administration with respect to antigen is critical in determining a state of enhancement or suppression. The immune response was suppressed only when LPS was added before or together with antigen, even when the addition of both LPS and antigen was delayed for a day ( Table 2 ). These data confirm earlier in vivo and in vitro observations (14, 15) . We document these experiments here because they provide the rationale for experiments described below.
It has been found (7) (Table 3) . Effectiveness of T-cell elimination is demonstrated by the lack of responsiveness in cultures to which TNS had not been added and was verified by the absence of a mitotic response to the T-cell mitogen concanavalin A (data not shown). Besides showing that suppression by LPS can occur in the absence of T cells, this experiment further implies that suppression is not due to limited T-cell helper function because the addition of a T-cell replacing factor did not restore responsiveness. Experiments using other helper factors [allogeneic effect factor (16), T-cell replacing factor (17) , and B-cell dif- (2)] yielded similar results. Removal of macrophages by passage of spleen cells over Sephadex G-10 columns also did not affect the ability of LPS to inhibit antibody production. Our data are not shown here because this observation has been documented (3) .
Characterization of the Suppressor Cell. Taken together, our experiments pointed to the possibility that LPS inhibits antibody formation by activating suppressor B cells. We attempted, therefore, to design an assay for suppressor B cells. A procedure that had previously succeeded in the identification of concanavalin A-induced suppressor T cells was used as a guide for devising this system. Concanavalin A, a mitogen for T cells, was found to inhibit antibody production in vitro when added to cultures at the start. Cells obtained from cultures stimulated with concanavalin A for 1 or 2 days inhibit antibody formation of fresh spleen cell cultures to which they are added together with antigen. The activity of the suppressor T cells could be distinguished from the inhibitory activity of concanavalin A itself through the use of a-methylmannoside, which competes with concanavalin A for its receptor on lymphocytes (18, 19) . No such competitor has been described for LPS. Thus, using a similar procedure for the detection of LPS-induced suppressor B cells, we had to circumvent the problem of transfer of LPS. We tried to take advantage of the finding that addition of LPS to spleen cells after 24 hr of culture no longer induced suppression of the immune response ( Table  2 ). Spleen cells were preincubated for 20-24 hr in the presence or absence of LPS and then transferred to cultures that had been set up and immunized 24 hr earlier. Generation of anti-SRBC PFCs was determined 3 days later. Spleen cells preincubated for 20 hr with LPS (but not spleen cells incubated without LPS) were found to be inhibitory for recipient cultures (Fig. 2) 10 ,g/ml). These cells were then harvested, washed, and added in increasing numbers to unseparated (C57BL/6 X DBA/2)F1 spleen cell (recipient) cultures that had been initiated 24 hr previously in the presence of SRBC. Recipient cultures contained the appropriate cell number and volume so that 107 cells in 1 ml was achieved after additions were made. The dashed line represents the response of control cultures to which no cells were added.
(3). We tested this possibility directly by preparing populations of CR+ and CR-cells that were cultured for 24 hr with and without LPS and subsequently were added to antigen-stimulated recipient cultures. The results showed that CR+ cells activated by LPS can suppress the immune response. Cells from the CR-fraction of spleen cells did not generate suppressor activity in response to treatment with LPS (Fig. 4) .
Because this experiment strengthened the view that the cell mediating LPS-induced suppression was a B cell, further efforts were made to characterize the LPS-induced suppressor cell serologically. Portions of Sephadex-fractionated cells cultured for 20 hr in the presence or absence of LPS were treated in a two-step cytolytic procedure with cell surface antigen-specific antisera and complement. Antisera directed against the following cell surface markers were tested for their ability to abrogate suppression of LPS-activated spleen cells.
Wak. LPS-activated C57BL/6H-2k spleen cells treated with
anti-Iak antiserum and complement no longer displayed inhibitory activity. Anti-Iak antiserum reacted with approximately 40% of splenic B cells, with macrophages, and with a small fraction of T cells (Fig. 5A) . Ig and Thy-1.2. Spleen cells cultured with LPS lost their ability to suppress after treatment with purified anti-IgM antisera and anti-F(ab)2 of IgG1 antisera but not after treatment with anti-Thy-i antiserum. These data indicate that the cell type responsible for LPS-induced suppression is a B cell rather than a T cell (Fig. 5 B and C) .
Ly-b-2.1. Ly-b-2.1 is an alloantigen expressed exclusively on B cells (5) . C57BL/6-Ly-b-2. I-StrB is a mouse strain congenic with C57BL/6, whose B cells express this surface marker. Treatment of LPS-activated cells with anti-Ly-b-2. 1 antiserum and complement eliminated suppressor cells in cultures of the congenic strain but not in the control cultures of (Ly-b-2.1 negative) C57BL/6 mice ( Fig. 5 D and E) .
Pc-i. This surface antigen is found on a small subpopulation of B cells and is associated with their differentiation into plasma cells. Treatment of LPS-stimulated cells from C57BL/6-Pc-i+ mice (a strain congenic in C57BL/6 whose cells express the Pc-I surface antigen) with anti-Pc-i antiserum and complement did not alleviate suppression (Fig. 5F ). Evidence for the existence of suppressor B cells has been reported also in systems that do not involve LPS. Zembala et al. (20) found that a CR+ theta-negative cell can suppress the cell-mediated hypersensitivity response to picryl chloride. Zan-Bar et al. (21) reported that cells bearing predominantly IgG can suppress the IgM response of IgM-and IgD-bearing cells. Similar to our findings, Perrson (22) It would appear that immunotherapy would be most effective if the balance of inhibitory and stimulatory effects of a given immunopotentiator could be manipulated to its desired advantage. Prerequisite for the means to achieve this is a clear understanding of the biological pathways involved. With regard to LPS, the work presented here might be a step in this direction.
